Chengchao Xu

Demoted CD4+ T-cell activity resulted from CTNNB1 mutations resists lenvatinib plus anti-PD1 in HCC

Abstract Hepatocellular carcinoma (HCC) patients frequently fail to respond to combined anti-PD1 immunotherapy, though pre-existing neoantigen-specific CD8⁺ T cells within tumor microenvironment are reinvigorated upon PD1 blockaded. Tumor-intrinsic mechanisms driving the therapeu...